Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MGAM | O43451 | 3/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | FNTB | P49356 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710256 | 1.00 | LMNA (0.45) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL20895866 | 1.00 | LMNA (0.45) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL10791245 | 1.00 | LMNA (0.45) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL12134313 | 1.00 | LMNA (0.45) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL1710307 | 1.00 | LMNA (0.45) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL8453582 | 1.00 | LMNA (0.45) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL12134329 | 1.00 | LMNA (0.45) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL1710535 | 0.97 | — | — | |
| SCHEMBL402873 | 0.87 | — | — | |
| SCHEMBL29124293 | 0.86 | SMN1; SMN2 (0.35) | LMNAALDH1A1HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6909010-B2 | Facile synthesis of symmetric esters of alkylenebisphosphonic acids | LOYOLA UNIVERSITY OF CHICAGO (US) | 2005-06-21 | — | — | US | claimed |
| US-20030060648-A1 | Facile synthesis of symmetric esters of alkylenebisphosphonic acids | LOYOLA UNIVERSITY OF CHICAGO | 2003-03-27 | — | — | US | claimed |
| WO-2002085918-A1 | A FACILE SYNTHESIS OF SYMMETRIC ESTERS OF ALKYLENEBISPHOSPHONIC ACIDS | LOYOLA UNIVERSITY OF CHICAGO (US) | 2002-10-31 | — | — | WO | claimed |
| US-20250092078-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS, INC. (US) | 2025-03-20 | — | — | US | disclosed |
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4301374-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | Deciduous Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117222414-A | Compounds for activating constant natural killer T-cells and methods for eliminating inflammatory senescent cells | 脱落性治疗公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2022187141-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20060160918-A1 | Curable compositions | KANEKA CORPORATION (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1652884-A1 | Curable compositions | Kaneka Corporation (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-1179567-B1 | CURABLE COMPOSITIONS | KANEKA CORP (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20050234257-A1 | Facile synthesis of symmetric esters of alkylenebisphosphonic acids | LOYOLA UNIVERSITY OF CHICAGO | 2005-10-20 | — | — | US | disclosed |
| US-6909010-B2 | Facile synthesis of symmetric esters of alkylenebisphosphonic acids | LOYOLA UNIVERSITY OF CHICAGO (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040029990-A1 | Curable compositions | KANEKA CORPORATION (JP) | 2004-02-12 | — | — | US | disclosed |
| US-20030060648-A1 | Facile synthesis of symmetric esters of alkylenebisphosphonic acids | LOYOLA UNIVERSITY OF CHICAGO | 2003-03-27 | — | — | US | disclosed |
| WO-2002085918-A1 | A FACILE SYNTHESIS OF SYMMETRIC ESTERS OF ALKYLENEBISPHOSPHONIC ACIDS | LOYOLA UNIVERSITY OF CHICAGO (US) | 2002-10-31 | — | — | WO | disclosed |
| EP-1179567-A1 | CURABLE COMPOSITIONS | KANEKA CORPORATION (JP) | 2002-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160918-A1 | Curable compositions | VCL, VIM, DNMT3L | LMNA 826/4885ALDH1A1 1207/4885HSD17B10 3980/4885 |
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | IL2, IL4, PBK | LMNA 990/4885ALDH1A1 1785/4885HSD17B10 4368/4885 |
| US-20030060648-A1 | Facile synthesis of symmetric esters of alkylenebisphosphonic acids | PHOSPHO1, ADH1C, PAICS | LMNA 2196/4885ALDH1A1 257/4885HSD17B10 39/4885 |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | IL2, PBK, IL4 | LMNA 893/4885ALDH1A1 1217/4885HSD17B10 4524/4885 |
| US-20250092078-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | IL2, PBK, IL4 | LMNA 945/4885ALDH1A1 1215/4885HSD17B10 4477/4885 |
| US-20050234257-A1 | Facile synthesis of symmetric esters of alkylenebisphosphonic acids | PHOSPHO1, PAPSS1, PHPT1 | LMNA 2187/4885ALDH1A1 577/4885HSD17B10 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.